Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001014084 | SCV001174751 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-02-05 | criteria provided, single submitter | clinical testing | The p.P672S variant (also known as c.2014C>T), located in coding exon 18 of the TSC2 gene, results from a C to T substitution at nucleotide position 2014. The proline at codon 672 is replaced by serine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001054876 | SCV001219234 | benign | Tuberous sclerosis 2 | 2023-07-12 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001054876 | SCV002040667 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003117691 | SCV003798567 | uncertain significance | not provided | 2022-08-03 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003994192 | SCV004813669 | uncertain significance | not specified | 2024-02-04 | criteria provided, single submitter | clinical testing |